17/05/2024 – AB Science communicates a corrective statement on the consolidated accounts as of December 31, 2023 Download PDF Post navigationPreviousPrevious post:Annual financial results as of 31 December, 2023NextNext post:AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSRelated PostsRevenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024AB Science provides an update on the microtubule program AB8939September 26, 2024AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
